Detailed Information for C01138

Basic information about inhibitors

IPAD-DB ID C01138
Name Tauroursodeoxycholic acid
Category Natural compounds
2D Structure
3D Structure
Molecular Formula C 2 6 H 4 5 N O 6 S
Molecular Weight 499.7g/mol  
IUPAC Name 2-[[(4R)-4-[(3R, 5S, 7S, 8R, 9S, 10S, 13R, 14S, 17R)-3, 7-dihydroxy-10, 13-dimethyl-2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid
InChI InChI=1S/C26H45NO6S/c1-16(4-7-23(30)27-12-13-34(31, 32)33)19-5-6-20-24-21(9-11-26(19, 20)3)25(2)10-8-18(28)14-17(25)15-22(24)29/h16-22, 24, 28-29H, 4-15H2, 1-3H3, (H, 27, 30)(H, 31, 32, 33)/t16-, 17+, 18-, 19-, 20+, 21+, 22+, 24+, 25+, 26-/m1/s1
InChIKey BHTRKEVKTKCXOH-LBSADWJPSA-N
Canonical SMILES CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C
PubChem CID 9848818
DrugBank Accession Number -
CAS Registry Number 14605-22-2

Biological activity data

Ki -
EC50 -
IC50 -
Inhibition -
Toxicity -
ROS(reactive oxygen species) -
Metal Chelating -
BBB(blood-brain barrier) -
Target Protein Tau protein
Effects Short-term treatment with TUDCA attenuates Aβ deposition in APP/PS1 mice, reduce amyloidogenic processing of APP and Aβ generation in APP/PS1 mice, prevent tau hyperphosphorylation
Research Models In APP/PS1 mice
Main Source Bear bile
Ref. Link

Physicochemical properties

Molecular Weight(Computed by SwissADME) 499.7
Hac(Computed by SwissADME) 34
Volume(Computed by ADMETlab 2.0) 503.637
Density(Computed by ADMETlab 2.0) 0.991
nRing(Computed by ADMETlab 2.0) 4
MaxRing(Computed by ADMETlab 2.0) 17
nHet(Computed by ADMETlab 2.0) 8
fChar(Computed by ADMETlab 2.0) 0
nRig(Computed by ADMETlab 2.0) 23
Flexibility(Computed by ADMETlab 2.0) 0.348
Stero Centers(Computed by ADMETlab 2.0) 10
LogS(Computed by ADMETlab 2.0) -2.575
LogD(Computed by ADMETlab 2.0) 1.554

ADMET properties

logP(Computed by ADMETlab 2.0) 0.424
TPSA(Computed by SwissADME) 132.31
Hbond Acceptor(Computed by SwissADME) 6
Hbond Donor(Computed by SwissADME) 4
Rotatable Bonds(Computed by SwissADME)

Pharmacokinetics

GI Absorption(Computed by SwissADME) Low
BBB(blood-brain barrier) Permeant(Computed by SwissADME) No
P-gp Substrate(Computed by SwissADME) Yes
CYP1A2 Inhibitor(Computed by SwissADME) No
CYP2C19 Inhibitor(Computed by SwissADME) No
CYP2C9 Inhibitor(Computed by SwissADME) No
CYP2D6 Inhibitor(Computed by SwissADME) No
CYP3A4 Inhibitor(Computed by SwissADME) Yes
log Kp(Skin Permeation)(Computed by SwissADME) -8.13

Druglikeness

Lipinski(Computed by SwissADME) 0
Ghose(Computed by SwissADME) 3
Veber(Computed by SwissADME) 0
Egan(Computed by SwissADME) 1
Muegge(Computed by SwissADME) 0
Bioavailability Score(Computed by SwissADME) 0.56